Anirban Basu1, Lee J Barton2, Heidi Fischer2, Kristi Reynolds2, David E Arterburn3, Douglas Barthold4, Anita Courcoulas5, Cecelia L Crawford6, Peter N Fedorka7, Benjamin B Kim8, Edward C Mun8, Sameer B Murali9, Robert E Zane8, Karen J Coleman10. 1. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Departments of Pharmacy, Health Services, and Economics, University of Washington, Seattle, Washington. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. 3. Kaiser Permanente Washington Health Research Institute, Seattle, Washington. 4. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, Washington. 5. Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 6. Regional Nursing Research Program, Kaiser Permanente Southern California, Pasadena, California. 7. Department of Surgery, Kaiser Permanente San Bernardino Medical Center, Kaiser Permanente Southern California, Ontario, California. 8. Department of Surgery, Kaiser Permanente South Bay Medical Center, Kaiser Permanente Southern California, Harbor City, California. 9. Center for Healthy Living, Kaiser Permanente San Bernardino Medical Center, Kaiser Permanente Southern California, Fontana, California. 10. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. Electronic address: karen.j.coleman@kp.org.
Abstract
BACKGROUND: Comparative evidence is needed when deciding which bariatric operation to undergo for long-term cardiovascular risk reduction. OBJECTIVES: The Effectiveness of Gastric Bypass vs. Gastric Sleeve for Cardiovascular Disease (ENGAGE CVD) study compared the effectiveness of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) operations for reduction of the American College of Cardiology and the American Heart Association-predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk 5 years after surgery. SETTING: Data for this study came from a large integrated healthcare system in the Southern California region of the United States. This is one of the most ethnically diverse (64% non-White) bariatric populations in the literature. METHODS: The ENGAGE CVD cohort consisted of 22,095 patients who underwent VSG or RYGB from 2009-2016. The VSG and RYGB were compared using a local instrumental variable approach to address observed and unobserved confounding, as well as to conduct heterogeneity of treatment effects for patients of different age groups, baseline-predicted 10-year CVD risk using the ASCVD risk score, and those who had type 2 diabetes (T2D) at the time of surgery. RESULTS: Patients (2771 RYGB and 6256 VVSG) were primarily women (80.6%), Hispanic or non-Hispanic Black (63.7%), and 46 ± 10 years of age, with a body mass index of 43.40 ± 6.5 kg/m2. The predicted 10-year ASCVD risk at surgery was 4.1% for VSG and 5.1% for RYGB, decreasing to 2.6% for VSG and 2.8% for RYGB 1 year postoperatively. By 5 years after surgery, patients remained with relatively low risk levels (3.0% for VSG and 3.3% for RYGB) and there were no significant differences in predicted 10-year ASCVD risk between VSG and RYGB at any time. CONCLUSION: Predicted 10-year ASCVD risk was low in this population and remained low up to 5 years for those with diabetes, Black and Hispanic patients, and older adults. Literature reporting significant differences between VSG and RYGB in 10-year ASCVD risk may be a result of residual confounding.
BACKGROUND: Comparative evidence is needed when deciding which bariatric operation to undergo for long-term cardiovascular risk reduction. OBJECTIVES: The Effectiveness of Gastric Bypass vs. Gastric Sleeve for Cardiovascular Disease (ENGAGE CVD) study compared the effectiveness of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) operations for reduction of the American College of Cardiology and the American Heart Association-predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk 5 years after surgery. SETTING: Data for this study came from a large integrated healthcare system in the Southern California region of the United States. This is one of the most ethnically diverse (64% non-White) bariatric populations in the literature. METHODS: The ENGAGE CVD cohort consisted of 22,095 patients who underwent VSG or RYGB from 2009-2016. The VSG and RYGB were compared using a local instrumental variable approach to address observed and unobserved confounding, as well as to conduct heterogeneity of treatment effects for patients of different age groups, baseline-predicted 10-year CVD risk using the ASCVD risk score, and those who had type 2 diabetes (T2D) at the time of surgery. RESULTS: Patients (2771 RYGB and 6256 VVSG) were primarily women (80.6%), Hispanic or non-Hispanic Black (63.7%), and 46 ± 10 years of age, with a body mass index of 43.40 ± 6.5 kg/m2. The predicted 10-year ASCVD risk at surgery was 4.1% for VSG and 5.1% for RYGB, decreasing to 2.6% for VSG and 2.8% for RYGB 1 year postoperatively. By 5 years after surgery, patients remained with relatively low risk levels (3.0% for VSG and 3.3% for RYGB) and there were no significant differences in predicted 10-year ASCVD risk between VSG and RYGB at any time. CONCLUSION: Predicted 10-year ASCVD risk was low in this population and remained low up to 5 years for those with diabetes, Black and Hispanic patients, and older adults. Literature reporting significant differences between VSG and RYGB in 10-year ASCVD risk may be a result of residual confounding.
Authors: John A Batsis; Michael G Sarr; Maria L Collazo-Clavell; Randal J Thomas; Abel Romero-Corral; Virend K Somers; Francisco Lopez-Jimenez Journal: Am J Cardiol Date: 2008-07-17 Impact factor: 2.778
Authors: Anita P Courcoulas; Steven H Belle; Rebecca H Neiberg; Sheila K Pierson; Jessie K Eagleton; Melissa A Kalarchian; James P DeLany; Wei Lang; John M Jakicic Journal: JAMA Surg Date: 2015-10 Impact factor: 14.766
Authors: Jeffrey I Mechanick; Caroline Apovian; Stacy Brethauer; W Timothy Garvey; Aaron M Joffe; Julie Kim; Robert F Kushner; Richard Lindquist; Rachel Pessah-Pollack; Jennifer Seger; Richard D Urman; Stephanie Adams; John B Cleek; Riccardo Correa; M Kathleen Figaro; Karen Flanders; Jayleen Grams; Daniel L Hurley; Shanu Kothari; Michael V Seger; Christopher D Still Journal: Endocr Pract Date: 2019-11-04 Impact factor: 3.443
Authors: Sofia Castro Oliveira; J S Neves; P Souteiro; J Pedro; D Magalhães; V Guerreiro; R Bettencourt-Silva; M M Costa; A Varela; I Barroso; P Freitas; D Carvalho Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: Teresa N Harrison; Ronald D Scott; T Craig Cheetham; Shen-Chih Chang; Jin-Wen Y Hsu; Rong Wei; Deborah S Ling Grant; Susan H Boklage; Victoria Romo-LeTourneau; Kristi Reynolds Journal: Cardiovasc Drugs Ther Date: 2018-08 Impact factor: 3.727